1.Bioresorbable scaffold with minimum profile diameterThe scaffold is compatible with 4 ~ 6F sheath and is applicable to fine infant blood vessels of newborn.2.High post-expansion limitThe post-expansion limit at the time of implantation is nominal diameter +1mm.3.Secondary intervention expansionThe breakpoint design of multiple through-holes is preset on the struts of the scaffold to ensure the circumferential deconstruction as soon as possible after 6 months, which is conducive to secondary intervention expansion when necessary, and does not restrict the short-term growth of blood vessels.4.Reasonable degradation profileEffective support for 6 months and complete degradation in about 2 years, without restricting long-term growth of blood vessels.
The world's thinnest scaffold with 70 μm , the world's only iron-based bioresorbable technology path.
The breakthrough 118mm length, can cover the lesion length up to 200mm by overlapping use which
can meet the real world clinical application needs.
3.Excellent operation performance
The scaffold is compatible with 5F catheter and has excellent visibility. The nominal diameter of the post
expansion limit is +0.75mm.
The content of sirolimus is 1.4μg/mm2, with most of the drug being located on abluminal surface of the
struts.
Effective support for 6 months and fully degradable in about 1.5 years, allowing secondary intervention
expansion when necessary.
